A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults

Inclusion criteria

• Able and willing to provide a written informed consent
• Plan to undergo elective surgery under general anesthesia；
• ≥18 years old
• Meet the weight standard
• Conform to the ASA Physical Status Classification
• Expected postoperative hospital stay ≥72 hours
• PONV risk factors ≥3

Exclusion criteria

• Subjects with vomiting and/or retching and nausea occurred before surgery
• Subjects with a history of vestibular disease, central nervous system and other system diseases
• Subjects with a previous history of chronic nausea or vomiting/retching
• Subjects with a history of myocardial infarction or unstable angina pectoris
• Subjects with atrioventricular block or cardiac insufficiency
• Subjects with a history of ischemic stroke or transient ischemic attack
• Subjects with poor blood pressure control after medication
• Abnormal electrocardiogram
• Abnormal values in the laboratory
• Allergic to a drug ingredient or component
• Received treatment with potential antiemetic effects before starting the investigational product
• Subjects who received chemotherapy prior to surgery
• Use of drugs that affect the antiemetic effect, and the time between the last use of the test drug and the start of the time is less than 5 half-lives
• Plan to receive local anesthesia only or total intravenous anesthesia only
• Subjects who are expected to require an in-situ nasogastric tube or orogastric tube after completion of surgery
• Subjects expected to be transferred to the ICU at the end of surgery
• Pregnant or nursing women
• No birth control during the specified period of time
• Participated in clinical trials of other drugs (received experimental drugs)
• The inestigators determined that other conditions were inappropriate for participation in this clinical trial